Lack of correction of secondary hyperparathyroidism long term after kidney transplantation despite good graft function

• Type of Material: Article
• Authors: Enrique Rojas-Campos, Emory University; Francesca Cardarelli, Emory University; Paolo Raggi, Emory University
• Language: English
• Date: 2009-02
• Publisher: Oxford University Press (OUP): Policy B
• Publication Version: Final Published Version
• Copyright Statement: © The Author [2008].
• License: Creative Commons Attribution-NonCommercial 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1093/ndtplus/sfn172
• Title of Journal or Parent Work: NDT Plus
• ISSN: 1753-0784
• Volume: 2
• Issue: 1
• Start Page: 92
• End Page: 93
• Grant/Funding Information: Dr. E. Rojas is supported by a training grant from Genzyme Therapeutics; Dr. Paolo Raggi has received research grants from and he is part of a Medical Advisory Board for Genzyme Therapeutics.
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, General

Abstract

Secondary hyperparathyroidism (SHPT) and its associated bone and vascular complications are highly prevalent in patients undergoing renal replacement therapy. Whether successful kidney transplantation corrects SHPT in the majority of patients with a functioning graft is unclear. In the context of an ongoing, randomized study on the effects of vitamin D therapy in post-transplant patients, we reviewed the clinical data of 150 consecutive kidney or kidney–pancreas transplant recipients with a functioning graft a minimum of 1 year after transplantation at our institution.